Urachal Adenocarcinoma: A Rare Primary Cancer Managed With FOLFOX Chemotherapy.

Cureus

Hematology and Oncology, Florida Cancer Specialists, Fleming Island, USA.

Published: August 2023

Urachal adenocarcinoma (UA) represents a rare subset of bladder tumors involving a urachal remnant. Incidental gross hematuria is often the only presenting symptom, with patients often presenting late in their course, thereby imparting an overall poor prognosis. Although there are prior case reports, there is little literature reported and no standardized treatment guidelines. We report a case of a middle-aged male who presented with incidental gross hematuria after a fall. Workup indicated the presence of a calcified bladder dome mass and pathology reported a primary urachal adenocarcinoma with pelvic nodal involvement. Patient underwent surgical resection and subsequent adjuvant, systemic chemotherapy regimen with leucovorin, fluorouracil, and oxaliplatin (FOLFOX). We hope to bring greater awareness to this rare cause of bladder malignancy.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10510567PMC
http://dx.doi.org/10.7759/cureus.43849DOI Listing

Publication Analysis

Top Keywords

urachal adenocarcinoma
12
incidental gross
8
gross hematuria
8
urachal
4
adenocarcinoma rare
4
rare primary
4
primary cancer
4
cancer managed
4
managed folfox
4
folfox chemotherapy
4

Similar Publications

Invasive mucinous urachal adenocarcinoma: A case report of surgical management and insights from the literature.

Int J Surg Case Rep

December 2024

Faculty of Medicine, Polytechnic University of Palestine, Hebron, Palestine; Department of Urology, Governmental Hebron Hospital, Palestine.

Introduction And Importance: Urachal carcinoma (UrC) is a rare bladder malignancy originating from the urachus. Comprising around 90 % adenocarcinomas, most cases are invasive. Urachal adenocarcinoma is less common than its non-urachal counterpart and is recognized for its aggressive nature, often diagnosed at advanced stages with a poor prognosis.

View Article and Find Full Text PDF
Article Synopsis
  • * Most urachal cancers are classified as intestinal adenocarcinomas (90%), and they often occur in the lower urachal tube or bladder dome, leading to late diagnoses due to the silent nature of early stages.
  • * Treatment options for this aggressive cancer include surgery and chemotherapy (like cisplatin), with some patients showing positive responses to targeted therapies; a case study highlighted successful surgical treatment for a patient with advanced disease.
View Article and Find Full Text PDF

Urachal adenocarcinoma with cervical invasion misdiagnosed as primary cervical adenocarcinoma: a case report and literature review.

Front Oncol

September 2024

Department of Gynecology and Obstetrics, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China.

Article Synopsis
  • * This case study details a female patient misdiagnosed with cervical adenocarcinoma, who eventually underwent multiple surgeries and chemotherapy after being correctly identified with urachal adenocarcinoma that spread to the bladder and vagina.
  • * The findings emphasize the need for thorough histopathological evaluation for accurate diagnosis and suggest that anterior pelvic exenteration may be an effective treatment for local recurrences of UrC, although more research is needed.
View Article and Find Full Text PDF

Urachal adenocarcinoma is a rare and aggressive bladder cancer involving the urachus, an embryological fibrous remnant of the allantois extending from the bladder to the umbilicus. Usually discovered in the advanced stages, this cancer can commonly present with a poor prognosis. We report a case of a 34-year-old male patient with an unremarkable medical history who presented to the emergency department with severe, sudden onset, sharp abdominal pain.

View Article and Find Full Text PDF

Introduction: Urachal carcinomas are uncommon malignant neoplasms comprising only 0.01% of all adult cancers. Most patients were aged from 58 to 64 years at diagnosis with 60 years being the median.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!